Physician profile
Albert S Rohr
NPI 1801889886
$3,471.59
in general payments reported to CMS, 2019-2025
27 companies · $415 in 2025
The $415 reported for 2025 was less than what a typical Clinical & Laboratory Immunology (Allergy & Immunology) provider received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,177 · 2020: $123 · 2021: $84.89 · 2022: $432 · 2024: $240 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $337.57 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $283.15 | 2021-2022 | |
| Optinose US, INC. | $268.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $261.84 | 2019 | |
| Amarin Pharma, INC. | $250.28 | 2019 | |
| Abbvie INC. | $225.97 | 2024-2025 | |
| Pharming Healthcare, INC. | $182.26 | 2019 | |
| Glaxosmithkline, LLC. | $173.89 | 2019 | |
| Merck Sharp & Dohme LLC | $126.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.52 | 2019 | |
| Insmed, INC. | $125.17 | 2022 | |
| Paratek Pharmaceuticals, INC. | $122.90 | 2020 | |
| Alexion Pharmaceuticals, INC. | $120.82 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $119.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $109.26 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $108.80 | 2022 | |
| Shire North American Group INC | $101.93 | 2019 | |
| Amgen INC. | $78.48 | 2025 | |
| Genentech USA, INC. | $73.84 | 2019 | |
| Csl Behring | $66.91 | 2019 | |
| Bio Products Laboratory USA, INC. | $44.98 | 2019 | |
| Kaleo, INC. | $40.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.24 | 2019 | |
| Alk-Abello, INC | $33.28 | 2019 | |
| Octapharma USA, INC. | $22.48 | 2019 | |
| Circassia INC. | $17.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Rohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.